REN 850

Drug Profile

REN 850

Alternative Names: Leukocyte trafficking inhibitor

Latest Information Update: 15 Jun 2005

Price : $50

At a glance

  • Originator Renovis
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Multiple sclerosis

Most Recent Events

  • 13 Jun 2005 Discontinued - Preclinical for Autoimmune disorders in USA (PO)
  • 13 Jun 2005 Discontinued - Phase-I for Multiple sclerosis in USA (PO)
  • 14 Feb 2005 Phase-I clinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top